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Introduction
Schizophrenia is a mental illness characterized by cognitive impairment as well as positive and negative symptoms. Since many patients require lifelong medication treatment, it is essential that patients are exposed to optimal treatment strategies with a balance between efficacy and tolerability (Hasan et al., 2012) . During the course of treatment, treatment failures can arise from a number of factors related to patients (poor insight, financial constraints, missed appointments, ignoring and misinterpreting instructions, abrupt termination of treatment), healthcare providers (poor therapeutic relationship with patients, failure to explain medications/treatment plans adequately), and health systems (unavailability of insurance coverage, poor access to healthcare services) (Young et al., 1999) . Often clinicians cannot determine the causes of treatment failure and therefore cannot make the appropriate, tailored intervention to reverse or prevent the treatment failure.
At times during their treatment, the majority of patients with schizophrenia will be partially or fully non-adherent (Marder, 2013) . Partially and non-adherent patients are at risk of psychotic exacerbation and/or relapse, and non-adherence can also create difficulties for the clinician (e.g., difficulty evaluating treatment response), patients and their caregivers (poorer prognosis and increased burden of disease), and the healthcare system (e.g., hospitalization costs and treatment delivery) (Velligan et al., 2009) . Despite attempts at interventions, adherence continues to be a major problem for patients with schizophrenia and is the most modifiable cause for relapse. In general, non-adherence is under-recognized by clinicians in their own patients, though acknowledged as an overall issue (Byerly et al., 2005) . Treatment models for patients with schizophrenia are highly variable and can include individual, family, group, community, and mixed-treatment modalities (Zygmunt et al., 2002) . Approaches to management of antipsychotic (APS) medication can include self-reporting by the patient or reporting by a relative or caregiver, prescription renewals and pill counts, or assessment of saliva, urine, or A C C E P T E D M A N U S C R I P T 5 blood. Often, clinicians will rely on medication management reports from relatives or case managers, as opposed to a patient's self-report (Fenton et al., 1997) . External factors such as errors of omission, mistakes in dosage and timing, and taking medications that are not prescribed can also greatly affect the assessment of medication adherence (Fenton et al., 1997) . Consequently, improving medication adherence and, on a larger scale, medication management could potentially improve the patient's health outcome (e.g., lower hospitalization rates) and in turn lower medical costs (Gilmer et al., 2004) , and reduce family/caregiver burden (Hasan et al., 2012) . When a patient experiences a treatment failure, it is often difficult to determine if the cause is lack of adherence, lack of efficacy of the medication, or a drug interaction that reduces the efficacy of the APS.
The purpose of this study was to examine whether a novel intervention -providing patient APS blood levels (ABLs) to physicians -would affect physicians' predictions of treatment decisions that they would make for patients with schizophrenia under descriptive conditions using clinical vignettes. The treatment decisions of interest were not limited to prescription of APS medication but also included other interventions, such as referrals for psychotherapy and psychosocial education programs. In order to determine to what extent availability of ABLs guides predicted treatment decision-making, a clinician-reported outcome instrument, the Clinical Assessment of Schizophrenic Patients (CASP) was developed.
Methods

Inclusion criteria
Study participants were clinicians currently practicing as a psychiatrist or as a prescribing nurse in the US (nurse practitioner or clinical nurse specialist), currently treating patients with schizophrenia, and able to speak and read fluent English. The focus of the recruitment was for clinicians to give input into a tool to assess decisions when treating patients with schizophrenia.
The focus was not on use of ABLs and this was not a criterion for entry into the study.
Development of the CASP
The CASP was developed utilizing a modified Delphi Panel method (Linstone, 1975) (Evans, 1997) (Evans and Crawford, 2000) to gather consensus for important clinical decision making concepts during outpatient psychopharmacology visits through a set of cognitive interviews (for gathering and defining important concepts) and electronic questionnaire administration (for consensus of concepts) with practicing clinicians treating patients with schizophrenia. The This modified Delphi panel was conducted in two rounds with 14 clinicians in the field of schizophrenia. Study documents were developed and finalized based on iterative feedback and comments from the authors. During Round 1 of the modified Delphi panel, trained interviewers followed a semi-structured interview guide to elicit treatment options and methods of treatment decision-making for patients with schizophrenia. During Round 2 of the modified Delphi panel, the same 14 clinicians were asked to complete ranking exercises on a web-based survey system (i.e., SurveyMonkey®). These exercises were aimed at reaching consensus among the clinicians with respect to identifying and ranking the key concepts of treatment decision-making.
Once consensus was reached on the key concepts of treatment decision-making, the draft The CUT was created using the CASP as a basis to assess key pieces of information needed to make treatment decisions and changes. Vignette case studies used in conjunction with the CUT were developed to provide clinicians with different scenarios about patients with schizophrenia in which a variety of data was presented to describe the patient's situation and current mental status. In a pilot study, cognitive interviewing was performed with five clinical experts in the field of schizophrenia to evaluate the CUT with respect to content validity, and whether experts were able to read, understand and complete the tool using clinical vignettes. A field study of 30 clinical experts who did not participate in the pilot study was performed to ensure face validity of the newly developed tool as well as test the statistical properties of the CUT. A version of the CASP similar to the CUT that was used with the vignettes was developed for actual patient use.
Study assessments
The CUT was made up of three sections (see Supplemental Materials). Responses were based on the clinical vignettes. Section 1, Item 1, asks clinicians to review three general treatment options and report how likely they would be to make each treatment change for the patient using the following scale: 0 = "Very unlikely," 1 = "Unlikely," 2 = "Neither likely nor unlikely," 3 = "Likely," and 4 = "Very likely." In Section 1, Item 2, the tool provides the clinicians with 20 specific treatment options within five categories (medication, medication dose, acute intervention, change in psychiatric visits, and change in psychosocial regimen) and requires clinicians to report on how likely they would be to make each of these more specific treatment changes using the same scale as Section 1, Item 1. Section 1, Item 3, asks clinicians if additional information would allow them to make a better treatment plan. If they respond "yes" they are asked to proceed through six concepts that could influence their proposed treatment plan. If clinicians report that a concept would influence their decision-making process, they are asked to report how influential the information would be using the following scale: 0 = "Not at all influential," 1 = "Slightly influential," 2 = "Somewhat influential," 3 = "Very influential," and 4 = "Extremely influential." Section 2 is dependent on whether ABLs are provided for the specific case study patient. If ABLs are included for the case study patient, clinicians are asked to report whether the ABLs were helpful, whether the ABLs made them more confident in their predicted treatment decision, and whether the ABLs changed their predicted treatment decision.
Clinical Vignettes
Ten clinical vignettes (not based on actual patients) were developed to represent common clinical situations to be used as a prompt to elicit decision making from clinicians when treating
patients with schizophrenia ( Table 1) . The clinical vignettes contain information on patients with schizophrenia of varying severity levels. Severity levels were based on the clinical global impression severity scale (CGI-S), a 0-7 scale with 0 = not ill and 7 = extremely severe.
Information within these case studies includes descriptions of the patient's home life, physical appearance, and current medication.
Study design
This six week case-crossover study required participants (N = 30) to complete the CUT in conjunction with clinical vignettes (Fig. 1) . Nine of the 10 clinical vignettes were developed into two versions; one version included the patient's ABL (Version A) and the other version did not include the patient's ABL (Version B). One individual vignette was presented to the clinicians as Version B only in order to assess test-retest (TRT) reliability, referred to as vignette 10trt. The vignettes were presented at two time points with a washout period of 1-2 weeks between assessments. At each time point, nine randomly selected vignettes were used. The clinicians were also required to evaluate vignette 10trt at both time points. Except for 10trt, no two versions of the same vignette were presented at the same time point (i.e., clinicians who received a vignette with ABLs would not receive a vignette without ABLs at same time point). To minimize expectation bias, the clinicians were blinded about details of the vignettes (e.g., existence of two versions of vignettes or assessment of same or similar vignette at both timepoints.
Statistical Methods
TRT was conducted at the item-level using weighted kappa statistics. Known groups analysis was conducted for clinician global impression of severity groups using chi-square tests. No
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The analysis population for this study was defined as all clinicians who had completed all ten CUT (i.e., one CUT for each vignette presented) for at least one time point.
The following clinician characteristics at time point 1 were described using the full study sample.
These variables included: type of physician or clinician; type of practice/profession, size of practice (number of physicians), years of practice, number of patients with schizophrenia seen per week (on average), and number of patients with schizophrenia in practice (best estimate).
TRT analysis was conducted for each of the general treatment option item scores. Weighted kappa (kW) coefficients and associated 95% confidence intervals were calculated for the CUT items for time point 1 and 2 data. kW coefficients approximate intraclass correlation coefficients for ordinal data, and values of 0.70 or greater are evidence of acceptable TRT reliability for a scale (Beaton et al., 2002) ; (Nunnally, 1994) ; (Fleiss, 1981) ; (Guyatt et al., 2002) .
One-sample test of proportions (using z-statistic) was conducted to observe significant differences between the clinician responses "Yes" and "No" for the following questions: "Did having the ABLs available to you in the vignette change your clinical decision" and "Are you more confident in your decision based on the available ABL information?" based on each vignette. A significant p-value (p < 0.05) indicated a significant difference between proportion of "Yes" and "No" responses.
In addition, "shift tables" were created to note the exact changes on the CUT in WABL vignettes compared to ABL vignettes. Proportion of clinicians whose decision changed in the presence of ABL information was compared to the proportion of clinicians who decision did not change using a one-sample test of proportions.
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Results
Five clinicians participated in the pilot test which showed that readability and understandability of the CUT were good, and that only a few modifications were needed for the CUT. No new items were added to the CUT and clinicians understood the items' intent and corresponding response options. Based on the feedback, the authors determined the CUT and vignettes were capturing the different decisions to be made for patients with schizophrenia (i.e. the CUT), as well as capturing appropriate snap-shots of patients with schizophrenia (i.e. the vignettes). This finding demonstrates the content validity of the CUT. The CUT has not been used any other studies.
A total of 30 clinicians participated in the field study, with 29 completing both sets of vignettes.
One clinician failed to complete the second set of vignettes. Most clinicians participating in the field study identified themselves as psychiatrists (n = 21, 70%), and a majority of clinicians' work in a private practice (n = 17, 56.7%). Clinicians most frequently reported working in a practice with two to five clinicians (n = 9, 30.0%) or 6-20 clinicians (n = 9, 30.0%). The largest number of clinicians (n = 10, 33.3%) had practiced 10-20 years after residency, and clinicians (n = 9, 30.0%) most frequently saw an average of between 21 and 30 patients with schizophrenia per week. Additionally, most clinicians (n = 21, 70.0%) had more than 40 patients with schizophrenia in their practice. In general, clinicians utilized the full scale of the CUT based on each vignette (i.e., there was no predominance of a particular response).
TRT reliability
Clinical vignette 10trt was used for TRT reliability analysis, which showed that the recommended acute intervention item (kW = 0.388) was considerably below the threshold of acceptability (kW > 0.70), and the likeliness of medication change (kW = 0.696) was nearly
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12 within the threshold of acceptability. The likeliness of change in psychosocial regimen (kW = 0.849) was above the TRT threshold. Table 2 represents the analyses of shift in predicted treatment decisions in the ABL vignettes compared to the WABL vignettes for any treatment option (i.e., change in acute intervention, medication, or psychosocial therapy regimen). There was a significantly higher proportion (at least 89.7%) of clinicians whose predicted treatment decisions changed in the presence of ABLs 
Shift in clinical decisions between ABL and WABL vignettes for any treatment option
Change in predicted treatment decision based on available APS treatment information
Except for vignette 9, a majority of clinicians (60.7%-85.7%) responded that the availability of ABLs changed their predicted treatment decisions (Table 3) . Of note, a significantly higher ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 13 proportion (at least 69%) of clinicians reported this response for almost all vignettes aside from vignettes 3, 5, and 9 (p < 0.05).
Confidence in predicted treatment decision based on available ABLs
A significantly higher proportion of clinicians (78.6%-92.9%) responded that they were more confident in their decisions in the presence of ABLs (p = 0.002 for vignette 9, and p < 0.001 for all other vignettes). Confidence responses from the participating clinicians for each vignette are summarized in Table 4 .
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Discussion
Analysis of systemic drug concentrations has proven to be a valuable method in evaluation of APS non-adherence, reasons for poor tolerability, nonresponse at therapeutic doses, or pharmacokinetic drug-drug interactions (Hiemke et al., 2011) . However, there is no established method to show how clinicians might use ABLs in making treatment decisions. This study was performed to assess shifts in treatment decisions, and confidence in any predicted treatment decision with ABLs under a given set of therapeutic scenarios using the CUT.
The wide variety of responses provided by clinicians demonstrated full utilization of the CUT's scales. A pilot study in five clinicians prior to the beginning of this study supports the assumption that clinicians both understood the task at hand as well as how to use the CUT (data not shown).
The CUT was found to be reliable for all but acute interventions. The clinical decisions reported for recommending an acute intervention was considerably below the TRT threshold (kW = 0.388), possibly indicating that clinicians define acute intervention differently or that the use of acute interventions varies by practice location and setting.
Clinicians responded that they were more confident (78.6%-92.9%) in their decision making and (aside from vignette 9) clinicians (60.7%-85.7%) responded that the availability of ABLs changed their predicted treatment decision. These subjective findings, paired with the objective findings of the analyses of shift in predicted treatment decisions demonstrate that ABLs were reported by clinicians to be a valued part of the decision-making process.
Treatment decisions are based on multiple factors. Importantly, knowledge of medication and patient characteristics, particularly symptom severity and functional change allows for a better understanding of patient management, and the variety of interventions and causes of treatment failure. The results of this study suggest ABLs may be useful for treatment decision making.
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The CUT demonstrates a first step in capturing these types of decisions, though additional research in a real-world setting would be beneficial. In addition, the scale was administered in a US, English language-only clinician population using vignettes. Further work needs to be done on the utility of the CUT (and the CASP) for capturing clinical decision making in a clinical setting, regardless of the use of ABLs. If the scale is to be used internationally, appropriate linguistic validation efforts should be carried forward as well as needing to consider differences in clinical practice.
In summary, if more evidence supports the use of ABLs, this may increase the use of ABLs and lead to more objective information used when making treatment decisions in patients with schizophrenia. Improved outcomes for patients' due to ABLs would need to be shown in clinical trials. 
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